Bill Detail
S. 1862
Congress: 119
Title
ORPHAN Cures Act
Summary
Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures Act This bill modifies certain provisions under the Medicare Drug Price Negotiation Program with respect to orphan drugs. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The program does not apply to orphan drugs that are approved to treat only one rare disease or condition. The bill modifies these provisions so as to exclude any period in which a drug was an orphan drug from market approval calculations. It also excludes orphan drugs that are approved to treat more than one rare disease or condition from the program.
Sponsor
Sen. John Barrasso [R-WY]
Status
Read twice and referred to the Committee on Finance.
Status as of Aug 14, 11:15 AM · synced 7h ago
Introduced
2025-05-22
Data source mode: cache
Bill Engagement
Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures Act This bill modifies certain provisions under the Medicare Drug Price Negotiation Program with respect…
Lobbyists on the case
- Tiber Creek Group4 filings · 6 lobs
- Jonathon Jones2026 Q1Tiber Creek Group · Chief of Staff, Sen. Tom Carper (2001-2006); Legislative Director, Sen. Tom Carper (2001).
- Corey Malmgren2026 Q1
Prepared intelligence brief
Put this record in the joined picture.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.